Cell Targeting
2004
FOUNDED
M&A
STATUS
M&A
LATEST DEAL TYPE
$2.4M
LATEST DEAL AMOUNT
Description
Developer of a stem cell technology intended to take cell therapy products to a new level of performance. The company's stem cell technology uses peptides to coat therapeutic cells using techniques that do not modify cell physiology, enabling users to elevated performance of cell therapy products.
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
- Cleveland, OH
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Cell Targeting’s full profile, request a free trial.
Cell Targeting Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 28-Jan-2011 | $2.4M | 000 | 00.00 | Completed | Generating Revenue |
| 3. Angel (individual) | 01-Apr-2008 | 000 | 000 | Completed | Startup | |
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Grant | Completed | Startup |
Cell Targeting Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Defense Advanced Research Projects Agency | Government | 000 0000 | 000000 0 | |||
| Global Cardiovascular Innovation Center | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | ||
| Toucan Ventures | Other | Minority | 000 0000 | 000000 0 |